Crescendo Biologics Limited, a Cambridge, UK-based company focused on the discovery and development of human VH antibody fragment therapeutics, raised £17.5m ($28m) in a Series A financing.
The round was led by Imperial Innovations with participation from new investor Astellas Venture Management (AVM) and founding seed investor Sofinnova Partners. In conjunction with the funding, Rob Woodman of Imperial Innovations, joined Crescendo’s Board.
The company intends to use the funds to advance its inflammation and oncology programmes to the clinic.
Led by Mike Romanos, CEO, Crescendo Biologics uses its VH fragment discovery platform to advance in-house development programmes in inflammation and oncology. The company is establishing an internal pipeline including a topical biologic for psoriasis and multivalent products for oncology indications.